The impact of positive T-cell lymphocytotoxic crossmatch on intestinal allograft rejection and survival

Transplant Proc. 2000 Sep;32(6):1197-8. doi: 10.1016/s0041-1345(00)01181-7.
No abstract available

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Child
  • Daclizumab
  • Female
  • Follow-Up Studies
  • Graft Rejection / immunology*
  • Graft Rejection / prevention & control
  • Graft Survival*
  • Histocompatibility Testing*
  • Humans
  • Immunoglobulin G / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Intestines / transplantation*
  • Male
  • Muromonab-CD3 / therapeutic use
  • Postoperative Complications / classification
  • Postoperative Complications / epidemiology
  • Retrospective Studies
  • Survival Rate
  • T-Lymphocytes, Cytotoxic / immunology*
  • Time Factors
  • Transplantation, Homologous / immunology*
  • Transplantation, Homologous / mortality
  • Transplantation, Homologous / physiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Daclizumab